[Long-term effects of indobufen on several parameters of blood platelet function in subjects at thrombotic risk].
Indobufen (200 mg b.i.d., by os, for 21 days) was gave to 16 patients with atherothrombotic risk in which platelet function was valued. In this subjects, indobufen significatively reduced platelet aggregation, beta-thromboglobulin, platelet factor the 4th and alpha-platelet granules' intake. No side effects were found.